A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT05355402

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05355402
Other papers using this trial's data
  • Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk The New England journal of medicine, 2024-05-16 DOI, PubMed 38587249

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05355402. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-09 (actual); primary completion 2023-03-22 (actual). Results posted on 2026-04-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Condition
Hypertriglyceridemia
Condition
Atherosclerotic Cardiovascular Disease
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Olezarsen
Intervention (Drug)
Placebo
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05355402
Content hash
e5fa9d949111472e98f3e8e0d8ddf339dee377e538276c5a057014d82d48aaf3